Company intelligence / Profile preview

Seqker Biosciences

Ownership: Private
Development stage: Preclinical

Overview

Seqker Biosciences is advancing a personalized neoantigen peptide-based cancer vaccine. Their lead program is in a Phase I/IIb trial evaluating safety, immunogenicity, and preliminary efficacy in patients with advanced or high-risk solid tumors. The approach uses patient-specific tumor genomics to identify unique targets (neoantigens) for individualized vaccine design. As of early 2025, the trial is active but not recruiting new patients. No published clinical results are available yet.[1][2]

Therapeutic areas: Oncology
Modalities: Personalized neoantigen peptide vaccinesGenomic profiling/diagnostics[1][3][7]
Industry: Biotech

Drug pipeline

1 asset

Seqker lung cancer vaccine (public design)

Preclinical

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Seqker Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seqker Biosciences.

Explore the full profile